Stay updated on Soticlestat in Rare Epilepsies Clinical Trial
Sign up to get notified when there's something new on the Soticlestat in Rare Epilepsies Clinical Trial page.

Latest updates to the Soticlestat in Rare Epilepsies Clinical Trial page
- Check6 days agoChange DetectedThe page now shows that ENDYMION 1 (NCT03635073) has been terminated, with the termination reason citing negative results from related trials and indicating that supplementary data is no longer necessary.SummaryDifference0.1%

- Check13 days agoChange DetectedThe Locations section was revised to replace individual site entries with a consolidated list; new locations were added (e.g., Victoria, Ontario, Guangdong, Shanghai, Tel Aviv, Madrid, Navarre) while prior sites (Arizona, California, Colorado, etc.) were removed.SummaryDifference2%

- Check21 days agoChange DetectedThe Endymion 1 study (NCT03635073) has been terminated and closed. Takeda states this was due to negative results from related SKYLINE and SKYWAY studies and that supplementary data from TAK-935-18-001 is no longer necessary.SummaryDifference0.1%

- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedThe page footer now shows Revision: v3.3.2, replacing Revision: v3.2.0, with no changes to the trial details or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check49 days agoChange DetectedRemoved the notice about potential delays and updates due to a lapse in government funding and the NIH Clinical Center's operating status.SummaryDifference0.3%

- Check57 days agoChange DetectedThe ENDYMION 1 study (NCT03635073) has been terminated and closed by the sponsor due to negative results from related phase 3 trials, and this termination is noted on the Study Details page.SummaryDifference0.1%

Stay in the know with updates to Soticlestat in Rare Epilepsies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Soticlestat in Rare Epilepsies Clinical Trial page.